Filter By Industry
Filter By Tag

Press Room

NAPSRx Press releases

1 - 10 of 340 Press Releases

May 06, 2015
Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...

May 05, 2015
Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.

Apr 30, 2015
On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.

Apr 27, 2015
Eli Lilly’s breakthrough cancer treatment CYRAMZA® (ramucirumab) has received another approval from the U.S Food and Drug Administration (FDA) making this the fourth approved indication for the treatment.

Apr 24, 2015
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted priority review for Abbvie’s all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with...

Apr 21, 2015
Pfizer has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for  XALKORI® (crizotinib) to potentially treat patients with ROS1-positive non-small cell lung cancer (NSCLC).

Apr 16, 2015
The U.S. Food and Drug Administration (FDA) has approved Amgen’s Corlanor® (ivabradine) to treat chronic heart failure.

Apr 13, 2015
Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.

Apr 07, 2015
Bristol-Myers Squibb (BMS) will get exclusive access to uniQure’s gene technology platform based on a strategic collaboration between both companies to identify multiple targets in cardiovascular diseases.

Apr 01, 2015
ProAir® RespiClick is the first Breath-Actuated Dry-Powder Short-Acting Beta-Agonist (SABA) Inhaler to be approved by the FDA.

RSS Feed for NAPSRx Press Releases